Results 61 to 70 of about 33,911 (221)

Pregnancy-associated hemolytic uremic syndrome

Saudi Journal of Kidney Diseases and Transplantation, 2020
Pregnancy-associated hemolytic uremic syndrome (P-aHUS) is not an uncommon condition. It is considered a medical emergency that is associated with a high risk of mortality and serious morbidity.
Sami Alobaidi, Ammar AlDabbagh, Amany Alamoudi, Murad Almowarey, Ahmed Akl   +4 more
doaj   +1 more source

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 521-530, June 2026.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova, Nicolas Ulrich Edgar, Anton V. Rets   +2 more
wiley   +1 more source

Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

Thrombosis Journal, 2019
Background Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle.
Ramy M. Hanna, Noah Merin, Richard M. Burwick, Lama Abdelnour, Umut Selamet, Beshoy Yanny, Patrick Bui, Mary Fouad, Ira Kurtz   +8 more
doaj   +1 more source

Phenotypic manifestation of homozygous partial deletion of the chromosome 1 segment spanning CFHR3 region

Медицинская иммунология, 2020
This article presents two clinical cases of patients with a homozygous deletion of segment of chromosome 1, which covers regions of genes associated with complement factor H, in particular CFHR3.
I. A. Tuzankina, M. A. Bolkov, N. S. Zhuravleva, Yu. O. Vaseneva, Kh. Shinvari, O. V. Schipacheva   +5 more
doaj   +1 more source

Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report [PDF]

, 2015
INTRODUCTION: Thrombotic microangiopathies are a group of diseases presenting as microangiopathic hemolytic anemia, thrombocytopenia and end-organ dysfunction.
Abdulkadir Unsal, Cuneyt Akgol, David Kavanagh, Ekrem Kara, Elbis Ahbap, Mustafa Sevinc, Tamer Sakaci, Taner Basturk, Tim HJ Goodship, Tuncay Sahutoglu, Vicky Brocklebank, Yener Koc   +11 more
core   +1 more source

Periocular Pigmentation After Gemcitabine Monotherapy for Bladder Cancer: A Rare Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT A patient with advanced bladder cancer received antitumor therapy consisting of gemcitabine on days 1 and 8 combined with cisplatin and treliprimab on day 1. Severe periorbital hyperpigmentation occurred 30 min after gemcitabine infusion on day 8. Symmetrical diffuse hyperpigmentation of a dark brown hue with indistinct borders appeared around
Li Juan, Chen Weiping
wiley   +1 more source

Safety and efficacy of eculizumab in adult and pediatric patients with aHUS, with or without baseline dialysis [PDF]

, 2015
C
Hourmant, Maryvonne, Kincaid, John F, Legendre, Christophe M, Menne, Jan, van de Kar, Nicole CAJ, Vande Walle, Johan   +5 more
core   +1 more source

Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra, B. Botella, M. D. Martín‐Arranz, D. Ceballos, C. Martínez‐Pascual, A. Garrido, P. Varela, M. Moreta, E. Brunet‐Mas, Y. González‐Lama, E. Rodríguez‐González, M. Vicuña, J. P. Gisbert, I. Ordás, F. Argüelles‐Arias, J. Tosca‐Cuquerella, R. Vicente‐Lidón, M. Sierra‐Ausín, I. Rodríguez‐Lago, D. Martín‐Rodríguez, J. M. Paredes, B. Sicilia, I. García de la Filia, N. Jiménez, M. Barreiro‐de Acosta, E. Betoré, I. Ferrer‐Bradley, L. García‐Alles, J. M. Huguet, S. Castellet‐Farrús, M. J. García, A. Gutiérrez‐Casbas, Á. Ponferrada‐Díaz, L. Ramos, M. Calafat, I. Vera, C. Suárez‐Ferrer, E. Fernández‐Velado, S. Rodríguez‐Sánchez, A. Mínguez, A. Mancebo, J. Barrio, S. Lario, D. R. de La Cruz, Alejandro Hernández‐Camba, C. Rodríguez‐Gutiérrez, M. Chaparro, E. Ricart, L. Almenara‐Michelena, A. Balaguer, E. Domènech, P. Nos   +51 more
wiley   +1 more source

Primary Thrombotic Microangiopathy in Pediatric Patients

Global Pediatric Health
Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology .
Andrés David Aranzazu Ceballos MD, Lina María Martínez Sánchez MSc, Ana Paulina Pamplona Sierra MD, Daniela Vergara Yánez MD, Liliana Franco Hincapié PhD, Richard Baquero Rodriguez MD   +5 more
doaj   +1 more source

Atypical hemolytic uremic syndrome : update on the complement system and what is new [PDF]

, 2010
Atypical hemolytic uremic syndrome (aHUS) is a rare disease of microangiopathic hemolytic anemia, thrombocytopenia, and predominant renal impairment. It is characterized by the absence of Shiga toxin-producing bacteria as a triggering factor.
Dickenmann, Michael, Hirt-Minkowski, Patricia, Schifferli, Jürg A.   +2 more
core   +1 more source